NEW YORK (TheStreet) -- Carefusion (CFN) shares are up 0.87% to $59.99 in trading on Thursday following the release of the global medical technology manufacturer's second quarter earnings results before the opening bell today.

The company reported second quarter earnings of $173 million, or 99 cents per diluted share on an adjusted basis, on revenue of $1.07 billion. Analysts on average were expecting the San Diego-based company to report earnings of 80 cents per share on revenue of $1.01 billion.

Second quarter revenue for the company's medical systems and procedural solutions segments was up 10% to $645 million and 27% to $424 million, respectively.

Exclusive Report:Jim Cramer's Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates CAREFUSION CORP as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

"We rate CAREFUSION CORP (CFN) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

Image placeholder title

CFN

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.